AI Summary
✦ ClarthaAcutaas Chemicals is a pharmaceutical-intermediates manufacturer serving Indian and international markets. Its revenue spans regulated and generic API intermediates, specialty chemicals, and photoresist and electrolyte-additive products. These products support anti-infective, oncology, personal-care, agrochemical, semiconductor, and lithium-battery applications. Revenue grew 40.2% year-on-year, while profit increased 271.1%, indicating substantial operating leverage. Investor-meeting activity may improve visibility for its semiconductor and battery-chemical opportunities. Profitability is improving, but debt-to-equity of 2.08 means leverage can amplify ROE and increase financial risk. The reported ROE is unavailable, limiting assessment of capital efficiency despite the sharp profit increase. At 89.9 times earnings, the stock appears rich and likely trades at a premium to its growth rate. The key open question is whether newer semiconductor and battery products can justify this valuation without extending leverage further.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 10 analysts
Fundamentals
Fundamentals institutional score is 100 using growth durability 100.0.
Valuation
Valuation institutional score is 26 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 5 using mean target upside -7.1%; dispersion penalty 30; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 64 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 5 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 181.9% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.26). Confidence: 50%.
Live forward EPS implies next-12-month EPS of ₹71.10. Applying the stock's normalized valuation corridor produces a fair range of ₹1,294.73 to ₹3,380.09, with base value near ₹2,241.78 (-27.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹71.10
Forward P/E
43.8x
Base Fair Value
₹2,241.78
Fair Range
₹1,294.73 - ₹3,380.09
Upside To Base
-27.9%
Estimate Source
Live forward EPS
Growth Estimate
+67.1%
5Y Average
29.61
Current
88.87
Overvalued
47.54
Undervalued
18.21
5Y Average
15.75
Current
47.27
Overvalued
18.32
Undervalued
7.79
5Y Average
12.82
Current
15.40
Overvalued
16.22
Undervalued
8.29
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 87.5x Fair | -11% vs avg | +6.5% |
BIOCON LIMITED. BIOCONBiotechnology | +10.0% | 2.9% | 120.9x Premium | +23% vs avg | +18.3% |
SAI LIFE SCIENCES LIMITED SAILIFEBiotechnology | +11.7% | 16.1% | 85.4x Fair | -13% vs avg | +62.7% |
ONESOURCE SPECL PHARMA L ONESOURCEBiotechnology | +37.2% | -3.1% | — | — | -18.0% |
ACUTAAS CHEMICALS LIMITED trades in line with peers (92.0x vs avg 97.9x), reflecting a fair valuation within the Biotechnology cohort. Peers include ANTHEM BIOSCIENCES LTD, BIOCON LIMITED., SAI LIFE SCIENCES LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹322 CrJun 2026Latest net profit
₹76 CrJun 2026Latest EPS
₹9.27Jun 2026Net margin
34.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 142 | 164 | 162 | 220 | 171 | 244 | 271 | 304 | 206 | 305 | 391 | 422 | 322 |
| Expenses + | 117 | 145 | 138 | 180 | 145 | 195 | 204 | 220 | 155 | 209 | 237 | 241 | 213 |
| Operating Profit | 25 | 19 | 24 | 40 | 26 | 48 | 67 | 84 | 51 | 97 | 154 | 181 | 110 |
| OPM % | 18% | 11% | 15% | 18% | 15% | 20% | 25% | 28% | 25% | 32% | 39% | 43% | 34% |
| Other Income + | 1 | -30 | 3 | 9 | 2 | 9 | 2 | 6 | 16 | 9 | 6 | 15 | 4 |
| Interest | 1 | 1 | 3 | 2 | 4 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 9 | 9 |
| Profit before tax | 23 | -16 | 20 | 42 | 18 | 50 | 63 | 83 | 59 | 97 | 151 | 186 | 104 |
| Tax % | 25% | 31% | 23% | 24% | 25% | 25% | 28% | 24% | 24% | 25% | 26% | 26% | 27% |
| Net Profit + | 17 | -21 | 16 | 32 | 14 | 38 | 45 | 63 | 45 | 73 | 112 | 137 | 76 |
| EPS in Rs | 2.31 | -2.84 | 2.13 | 4.35 | 1.68 | 4.60 | 5.53 | 7.67 | 5.45 | 8.90 | 13.63 | 16.74 | 9.27 |
| Raw PDF | |||||||||||||
| YOY Sales Growth % | 9% | 11% | 6% | 18% | 20% | 49% | 68% | 38% | 20% | 25% | 44% | 39% | 57% |
| Material Cost % | 55.23% | 61.33% | 58.65% | 61.03% | 58.91% | 57.03% | 54.33% | 53.01% | 46.92% | 44.29% | 42.82% | 38.56% | 43.31% |
| Employee Cost % | 9.62% | 9.38% | 9.61% | 7.44% | 10.79% | 7.78% | 7.72% | 7.43% | 11.85% | 9.38% | 6.90% | 7.43% | 11.60% |
| Exceptional items | 0.00 | -31.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income normal | 1.10 | 1.26 | 2.87 | 8.55 | 1.90 | 8.58 | 2.17 | 5.69 | 16.02 | 8.97 | 6.34 | 14.55 | 4.48 |
| Exceptional items AT | 0 | -27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit excl Excep | 17 | 6 | 16 | 32 | 14 | 38 | 45 | 63 | 45 | 73 | 112 | 137 | 76 |
| Profit for PE | 17 | 6 | 16 | 32 | 14 | 38 | 45 | 63 | 45 | 73 | 112 | 137 | 76 |
| Profit for EPS | 17 | -21 | 16 | 32 | 14 | 38 | 45 | 63 | 45 | 73 | 112 | 137 | 76 |
| YOY Profit Growth % | 13% | -69% | -30% | 18% | -19% | 540% | 189% | 96% | 225% | 93% | 146% | 118% | 70% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript